| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/EURHEARTJ/EHV647 |
| P8608 | Fatcat ID | release_zty4lkdnyfhfdlyx6l6vy66h5u |
| P932 | PMC publication ID | 4872284 |
| P698 | PubMed publication ID | 26614823 |
| P50 | author | C. Noel Bairey Merz | Q23662175 |
| Eileen M Handberg | Q56983411 | ||
| Carl J Pepine | Q57013135 | ||
| André Rogatko | Q58345885 | ||
| Chrisandra L Shufelt | Q89697810 | ||
| Puja K Mehta | Q89697814 | ||
| Margo B Minissian | Q89697816 | ||
| Janet Wei | Q89697820 | ||
| Daniel S Berman | Q89697826 | ||
| John W Petersen | Q89697829 | ||
| R David Anderson | Q89697832 | ||
| Galen Cook-Wiens | Q89697835 | ||
| Leslee J Shaw | Q94570815 | ||
| P2093 | author name string | Jonathan J Shuster | |
| Louise E J Thomson | |||
| Garrett H Brown | |||
| P2860 | cites work | Patient non-compliance with paper diaries | Q24524128 |
| Clinical implications of the Women's Ischemia Syndrome Evaluation: inter-relationships between symptoms, psychosocial factors and cardiovascular outcomes | Q26861338 | ||
| Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). | Q33198363 | ||
| Diastolic dysfunction in women with signs and symptoms of ischemia in the absence of obstructive coronary artery disease: a hypothesis-generating study | Q33650828 | ||
| Effects of sex on coronary microvascular dysfunction and cardiac outcomes | Q33825527 | ||
| Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. | Q33967744 | ||
| Reproducibility of adenosine stress cardiovascular magnetic resonance in multi-vessel symptomatic coronary artery disease | Q34039759 | ||
| Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease | Q34316735 | ||
| Effects of ivabradine and ranolazine in patients with microvascular angina pectoris | Q34337197 | ||
| Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial | Q34544699 | ||
| Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina | Q34547211 | ||
| The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation | Q34559278 | ||
| Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial | Q34569443 | ||
| Development and validation of a short version of the Seattle angina questionnaire | Q34807134 | ||
| Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the Women's Ischemia Syndrome Evaluation. | Q35222305 | ||
| Emergence of Nonobstructive Coronary Artery Disease: A Woman's Problem and Need for Change in Definition on Angiography | Q36202061 | ||
| Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions | Q36485492 | ||
| Reproducibility of myocardial perfusion reserve - variations in measurements from post processing using commercially available software | Q37339320 | ||
| Cardiac risk factors and myocardial perfusion reserve in women with microvascular coronary dysfunction | Q37339431 | ||
| Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system | Q43593148 | ||
| Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). | Q44936581 | ||
| Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). | Q45038648 | ||
| Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. | Q45083293 | ||
| Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris | Q45238077 | ||
| Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus | Q45844952 | ||
| Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs | Q46416183 | ||
| Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes | Q46715059 | ||
| Interstudy reproducibility of quantitative perfusion cardiovascular magnetic resonance | Q46850464 | ||
| Angina pectoris in a contemporary population: characteristics and therapeutic implications. TIDES Investigators. | Q50859363 | ||
| Adaptive randomization procedures for the web-based randomization system RANDI2. | Q51466320 | ||
| Validation of the Short Form 36 (SF-36) health survey questionnaire among stroke patients. | Q52007374 | ||
| Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography: comparison with invasive technique. | Q52906468 | ||
| A brief self-administered questionnaire to determine functional capacity (The Duke Activity Status Index) | Q56928615 | ||
| 2013 ESC guidelines on the management of stable coronary artery disease | Q57243329 | ||
| Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography | Q61651540 | ||
| Symptoms of angina pectoris increase the probability of disability pension and premature exit from the workforce even in the absence of obstructive coronary artery disease | Q61875221 | ||
| Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem | Q67900095 | ||
| Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test | Q69813910 | ||
| Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease | Q72585308 | ||
| Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials | Q79464002 | ||
| Ischemic heart disease in women | Q82468268 | ||
| Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease | Q87415438 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| placebo-controlled trial | Q108853737 | ||
| P304 | page(s) | 1504-1513 | |
| P577 | publication date | 2016-05-14 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve | |
| P478 | volume | 37 |
| Q38904539 | Advanced Imaging and Diagnostic Methods in the Assessment of Suspected Ischemic Heart Disease in Women |
| Q89700406 | Angina: contemporary diagnosis and management |
| Q47190217 | Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials |
| Q93353860 | Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review |
| Q47171821 | Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial. |
| Q92319527 | Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory |
| Q39102158 | Drug Therapy for Stable Angina Pectoris |
| Q48022963 | Expert consensus document: A 'diamond' approach to personalized treatment of angina |
| Q53528056 | Extreme-Dipper Profile, Increased Aortic Stiffness, and Impaired Subendocardial Viability in Hypertension. |
| Q92618268 | How to Diagnose and Manage Angina Without Obstructive Coronary Artery Disease: Lessons from the British Heart Foundation CorMicA Trial |
| Q56761527 | Inverse association of MRI-derived native myocardial T1 and perfusion reserve index in women with evidence of ischemia and no obstructive CAD: A pilot study |
| Q39176512 | Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. |
| Q57191197 | Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction ancillary study |
| Q88734513 | Left ventricular diastolic dysfunction in women with nonobstructive ischemic heart disease: insights from magnetic resonance imaging and spectroscopy |
| Q47580858 | Mental stress peripheral vascular reactivity is elevated in women with coronary vascular dysfunction: Results from the NHLBI-sponsored Cardiac Autonomic Nervous System (CANS) study |
| Q38741610 | Myocardial perfusion imaging in women for the evaluation of stable ischemic heart disease-state-of-the-evidence and clinical recommendations |
| Q48582664 | Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine |
| Q26740252 | No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction |
| Q92477674 | Ranolazine Reduces Angina in Women with Ischemic Heart Disease: Results of an Open-Label, Multicenter Trial |
| Q38971758 | Ranolazine for stable angina pectoris |
| Q38377198 | Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function |
| Q26765421 | Ranolazine: A Contemporary Review |
| Q55386798 | Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. |
| Q30234726 | Sex differences in cardiovascular disease - Impact on care and outcomes |
| Q64091904 | Stable Angina Medical Therapy Management Guidelines: A Critical Review of Guidelines from the European Society of Cardiology and National Institute for Health and Care Excellence |
| Q48188618 | Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need |
| Q54444751 | Syncope and sudden cardiac death: some answers to clinical challenges. |
| Q38821307 | The Significance of the Late Na+ Current for Arrhythmia Induction and the Therapeutic Antiarrhythmic Potential of Ranolazine |
| Q38846938 | Treatment of Angina Pectoris Associated with Coronary Microvascular Dysfunction |
| Q89840343 | Treatment of coronary microvascular dysfunction |
| Q38671970 | Typical angina is associated with greater coronary endothelial dysfunction but not abnormal vasodilatory reserve |
| Q62632824 | Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive coronary artery disease) |
| Q89471695 | Women's health: making cardiovascular disease real |
Search more.